Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199985 | 1.00 | POLB (0.50) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL28799641 | 0.91 | POLB (0.53) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL5666376 | 0.91 | POLB (0.53) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL7794947 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL3449196 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL13471863 | 0.88 | POLB (0.50) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL3178721 | 0.88 | POLB (0.50) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL127179 | 0.88 | POLB (0.50) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4201132 | 0.88 | POLB (0.50) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL3896397 | 0.86 | POLB (0.48) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1706 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| CN-110191950-B | Compositions, methods and systems for identifying candidate nucleic acid agents | 爱普济德生物技术有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116286830-A | Aptamer | 中国人民解放军军事科学院军事医学研究院 | 2023-06-23 | — | — | CN | claimed |
| CN-115151263-A | Aptamers and uses thereof | 爱普济德生物技术有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-3519571-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR IDENTIFYING CANDIDATE NUCLEIC ACID AGENT | APTITUDE MEDICAL SYSTEMS INC (US) | 2022-07-27 | — | — | EP | claimed |
| CN-111053903-A | Application of compound of nucleic acid analogue carrying resonance atom | 深圳市纳诺艾医疗科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| EP-2935331-B1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-9296687-B2 | Modulators of HSP70/DnaK function and methods of use thereof | FOX CHASE CANCER CENTER (US) | 2016-03-29 | — | — | US | claimed |
| EP-2935331-A1 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | AbbVie Inc. (US) | 2015-10-28 | — | — | EP | claimed |
| US-8957014-B2 | Sensitization of tumor cells to radiation therapy through administration of endothelin agonists | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | claimed |
| JP-2006508086-A | — | — | 2006-03-09 | — | — | JP | claimed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | claimed |
| EP-1556073-A2 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING SOLID TUMORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | claimed |
| WO-2004085418-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | LUITPOLD PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | claimed |
| US-20040138121-A1 | Method and composition for preventing and treating solid tumors | DONEHEW FUND LIMITED PARTNERSHIP | 2004-07-15 | — | — | US | claimed |
| WO-2004037235-A2 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING SOLID TUMORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-05-06 | — | — | WO | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138121-A1 | Method and composition for preventing and treating solid tumors | EDNRB, EDNRA, PGF | POLB 240/4885LMNA 827/4885PDE3A 83/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | POLB 112/4885LMNA 201/4885PDE3A 1236/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | POLB 74/4885LMNA 834/4885PDE3A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.